Analysts who follow SAGE Therapeutics Inc (SAGE) on average expect it to gain 89.03% over the next twelve months. Those same analysts give the stock an average rating of Buy.
That average rating earns SAGE an Analyst Ranking of 29, which means it ranks higher than 29 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating SAGE a Buy today. Find out what this means to you and get the rest of the rankings on SAGE!
Why are Analyst Ratings Important?
You can learn a lot about a company from looking at it’s financial statements and comparing them to other companies. Analysts who cover an industry in depth can add even more to your research though. They typically follow a particular sector or industry very closely. They also pay attention to and ask questions on earnings conference calls and other events where they might learn information that does show up in the numbers.
InvestorsObserver takes the average rating from these analysts, and then percentile ranks those averages. This lets you compare stocks in a much more granular way than just seeing the typical five-tiered rating system used on most of Wall Street.
What's Happening With SAGE Therapeutics Inc Stock Today?
SAGE Therapeutics Inc (SAGE) stock is up 6.7% while the S&P 500 has fallen -0.13% as of 11:37 AM on Monday, Aug 9. SAGE has risen $2.76 from the previous closing price of $41.09 on volume of 372,251 shares. Over the past year the S&P 500 is higher by 31.85% while SAGE has fallen -17.75%. SAGE earned $11.84 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 3.7.
Click Here to get the full Stock Report for SAGE Therapeutics Inc stock.